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ABSTRACT
In the EORTC classification two types of primary cutaneous large B-cell lymphoma 
(PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) 
and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered 
important because of differences in prognosis (5-year survival >95% and 52%, respectively) 
and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is 
not generally accepted.
To establish a molecular basis for this subdivision in the EORTC classification we 
investigated the gene expression profiles of 21 PCLBCL by oligonucleotide microarray 
analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL 
into two distinct subgroups consisting of respectively 8 PCFCCL and 13 PCLBCL-leg. 
PCLBCL-leg showed increased expression of genes associated with cell proliferation, the 
proto-oncogenes Pim-1, Pim-2 and c-Myc, and the transcription factors Mum1/IRF4 and Oct-
2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis 
suggested that PCFCCL and PCLBCL-leg have expression profiles similar to that of germinal 
center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The 
results of this study suggest that different pathogenetic mechanisms are involved in the 
development of PCFCCL and PCLBCL-leg and provide molecular support for the subdivision 
used in the EORTC classification.
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INTRODUCTION
The term primary cutaneous B-cell lymphomas refers to a heterogeneous group of B-cell 
neoplasms, which present in the skin without evidence of extracutaneous disease.
1 A 
significant proportion of these primary cutaneous B-cell lymphomas are large cell 
lymphomas.
2-5 In the European Organization for Research and Treatment of Cancer (EORTC) 
classification for primary cutaneous lymphomas, two main groups of primary cutaneous large 
B-cell lymphomas (PCLBCL) are distinguished.
1 Most cases are included in the group of 
primary cutaneous follicle center cell lymphomas (PCFCCL). Histologically, these PCFCCL 
represent a spectrum with variable proportions of (small) centrocytes and centroblasts and 
sometimes a follicular growth pattern in early lesions, and diffuse infiltrates of generally large 
centrocytes (large cleaved cells) in tumorous lesions.
2-5 In the WHO classification such early 
lesions are classified as cutaneous follicle center lymphoma, whereas the tumorous lesions are 
classified as diffuse large B-cell lymphoma.
6 Clinically, these PCFCCL represent a well-
defined group of primary cutaneous B-cell lymphomas which often present with skin lesions 
confined to a limited skin area on the head or the trunk, rarely disseminate to extracutaneous 
sites, and –irrespective of the proportion of large cells or growth pattern- have an excellent 
prognosis (5-year survival of more than 95%).
1,7 Already in the first publication on this group 
of PCFCCL it was noted that patients presenting with skin tumors on the leg had a different 
clinical behaviour.
3 Recent studies demonstrated that patients with such a primary cutaneous 
large B-cell lymphoma of the leg (PCLBCL-leg) differ from PCFCCL by a higher age of 
onset, more frequent dissemination to extracutaneous sites, and a poorer prognosis (5-year 
survival of approximately 50%).
7,8 Histologically, these PCLBCL-leg show a predominance 
of tumor cells with round nuclei and, in contrast to the group of PCFCCL, strongly express 
Bcl-2 protein.
7-10 For these reasons these PCLBCL-leg were included as a separate entity in 
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the EORTC classification.
1 Distinction between these two types of PCLBCL is clinically 
important, since it dictates the first choice of treatment: radiotherapy in PCFCCL and 
anthracycline-based chemotherapy in PCLBCL-leg.
7 By following the WHO classification 
both groups will be lumped together in the group of diffuse large B-cell lymphoma, and all 
patients will be treated with anthracycline-based chemotherapy with or without radiotherapy. 
Although recent studies
11-13 confirmed that these PCLBCL-leg are a distinct group with an 
intermediate prognosis, the subdivision of primary cutaneous B-cell lymphomas into two 
main categories (PCLBCL-leg and PCFCCL) primarily based on site of presentation (leg 
versus other sites) has been much disputed.
14
Recent studies have started to evaluate the genetic mechanisms involved in the development 
and progression of these lymphomas. However, the number of studies published to date is still 
limited and specific cytogenetic abnormalities have not been identified yet. Most studies have 
focused on the differential expression of the Bcl-2 protein in the different groups of PCLBCL. 
Most authors agree that the Bcl-2 overexpression in the group of PCLBCL-leg is not 
associated with the t(14;18) translocation as observed in most follicular and some diffuse 
large B-cell lymphomas in lymph nodes.
9,14,16 In some cases it might result from 
chromosomal amplification of the Bcl-2 gene.
17,18 Recent comparative genomic hybridization 
(CGH) studies demonstrated 6q loss and 18q gain in a proportion of PCLBCL, but not in 
PCFCCL.
18 Inactivation of p15 and p16 tumor suppressor genes by promoter 
hypermethylation has been detected in 11% and 44% of PCLBCL, respectively.
19
In the present study we performed oligonucleotide microarray analysis on a large group of 
PCLBCL, including 8 PCFCCL and 13 PCLBCL-leg. The main purpose of this study was to 
find out if the two types of PCLBCL recognized in the EORTC classification have different 
gene expression profiles. Differences in the gene expression profiles might not only give 
insight in the pathogenetic mechanisms underlying the differences in clinical behavior 
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between the two types of PCLBCL, but they could also provide a rationale for future 
classifications of these PCLBCL, and result in the identification of genes and pathways, 
which might serve as diagnostic or prognostic markers or as potential targets for therapeutic 
intervention.
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MATERIALS AND METHODS
Patient selection
Pretreatment skin biopsies from 8 patients with PCFCCL with a diffuse large cell histology 
and 13 patients with PCLBCL-leg were included in this study. Only cases in which large 
neoplastic B-cells constituted 80% or more of the total number of infiltrating cells were 
selected. The diagnosis PCFCCL or PCLBCL-leg was based on the criteria of the EORTC 
classification.
1 Using the WHO-classification all cases were classified as diffuse large B-cell 
lymphoma.
6 In all patients there was no evidence of extracutaneous disease at time of 
diagnosis as assessed by adequate staging procedures including physical examination, 
complete blood cell counts, computed tomography of chest and abdomen and bone marrow 
biopsy.
Patients with a PCFCCL presented with localized skin lesions either on the scalp (5 cases) or 
trunk (3 cases). Histologically, seven cases showed a diffuse proliferation of predominantly 
large cleaved cells (large centrocytes), whereas in one case (no. 1) almost equeal numbers of 
large cleaved cells and large non-cleaved cells (centroblasts) were observed. In one case (no. 
6) small clusters of CD35+ follicular dendritic cells were seen suggesting a preceding 
follicular growth pattern. Immunostaining showed 15-20% (median 20%) admixed T-cells and 
few scattered CD68+ macrophages. Consistent with previous studies of our group the 
neoplastic B-cells were either completely negative for Bcl-2 protein or showed a weak staining 
on a minor proportion (<20%) of tumor cells.
The 13 patients with a PCLBCL-leg presented with skin tumors on one (11 cases) or both legs 
(2 cases) (Table 1). One patient presented with an additional skin tumor on the right cheek (no. 
9). Histologically, all cases showed diffuse infiltrates of centroblasts and immunoblasts, with 
in two cases (nos 17 and 18) a considerable admixture (ca. 30%) of large cleaved cells. The
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numbers of admixed T-cells varied between 5% and 20% (median 10%), and was on the 
average much lower than in the group of PCFCCL. Bcl-2 protein was strongly expressed by 
the large majority of tumor cells in 11 of 13 cases. In the other two cases (nos. 13 and 18) Bcl-
2 was expressed by 40% and less than 10% of the neoplastic B-cells, respectively. 
Oligonucleotide microarrays
Samples and microarrays were processed according to the manufacturer's protocol (available 
from Affymetrix, Santa Clara, CA, USA). In brief, on average between 20-60 µg RNA was 
isolated from 50 x 20 µm frozen sections with the RNeasy-kit (Qiagen,Hilden, Germany). 
Using the MessageAmp aRNA kit (Ambion, Huntingdon, United Kingdom) total RNA was 
reverse transcribed using an oligo(dT)-T7 promoter primer to prime first strand synthesis. 
After second strand synthesis, the purified cDNA product was in vitro transcribed using T7 
RNA polymerase, biotin-UTP and biotin-CTP to generate fragmented biotinylated aRNA.
Fragmented aRNA (15 µg) was hybridized to a Human Genome U95Av2 Array (Affymetrix), 
interrogating 12625 human transcripts, for 16 h at 45°C with constant rotation at 60 rpm. 
After hybridization, the microarray was washed, stained on an Affymetrix fluidics station and 
scanned with an argon-ion confocal laser with 488 nm excitation and 570 nm detection 
wavelengths. 
Data processing and analysis 
The array images were quantified utilizing the MicroArray Suite (MAS) v5.0 software 
(Affymetrix, Santa Clara, CA, USA). The average fluorescence intensity was determined for 
each microarray and then the output of each experiment was globally scaled to a target value 
of 200. Normalization of the data was performed using variant stability and normalization 
(VSN®, Stanford, USA), part of the R statistical software package (available at 
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www.bioconductor.org).
20 Gene expression patterns were further analyzed utilizing Spotfire￿
DecisionSite and Statistical Analysis of Microarrays (SAM)￿.
21 First unsupervised 
hierarchical clustering (i.e. based on the expression of all genes present at the microarray) was 
performed using Spotfire￿ DecisionSite. To correct for potential influences of the tumor 
microenvironment on expression data, a B-cell signature was generated to focus specifically 
on the genes expressed by the tumor cells. This B-cell signature consisted of all 7450 genes 
with a "present"-call in the datasets of at least one of four normal B-cell subsets (centroblasts, 
centrocytes, memory B-cells and naïve B-cells) generated by the same Affymetrix U95Av2 
Gene Chip (more information about the normal subsets are in the paper of Klein et al).
22 To 
further investigate differentially expressed genes in both subgroups the supervised 
comparison analysis technique Statistical Analysis of Microarrays (SAM)￿ was applied to 
compare gene expression patterns of PCFCCL and PCLBCL-leg. A false discovery rate of < 
than 1.0 was chosen to select genes that were significantly up- or down regulated. Gene 
expression data were transformed into z-scores as described previously and obtained output 
was visualized utilizing Spotfire￿ DecisionSite.
23
Quantitative real-time PCR 
Expression values of 6 differentiating genes between PCFCCL and PCLBCL-leg identified by 
microarray and Bcl-2 alpha and beta splicevariants were analyzed by quantitative PCR in 4 
samples from PCFCCL and 4 samples from PCLBCL-leg. cDNA synthesis was performed on 
1 µg total RNA after treatment with RQ1 DNase I (Promega, Madison, WI) using Superscript 
III reverse transcriptase (Invitrogen, Breda, the Netherlands) and an oligo(dT)12-18  primer 
(Invitrogen, Breda, the Netherlands) in a final volume of 20 µl. Real-time PCR was performed 
with the ABI-Prism 7700 instrument and the SYBR Green PCR Master Mix (Applied 
Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). The cycle parameters for these 
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transcripts and for the housekeeping genes U1A and RPS11 used for normalization were as 
follows: denaturing for 15 s at 95°C;annealing and extension for 60 s at 60°, for 40 cycles. 
The primer sequences (Invitrogen) of selected transcripts are given in Table 2. For analysis of 
Bcl-2 expression primer combinations detecting 2 different splice variants (Bcl-2 alpha and 
Bcl-2 beta) were used.
24 Data were evaluated using the SDS software version 1.9.1 (Applied 
Biosystems) and the second derivative maximum algorithm. Specificity of the PCR product 
was confirmed by agarose gel electrophoresis and subsequent DNA sequence analysis of test 
samples and melting curve analysis in the case of patient material. Serial dilutions of cDNA 
synthesized from different cell lines were used to generate the standard curves for the primer 
combinations. 
Immunohistochemistry 
From 5 PCFCCL and 11 PCLBCL-leg paraffin material was still available for additional 
immunohistochemical stainings with antibodies against Mum1/IRF4 and the proliferation 
marker Ki-67. Staining was performed on formalin-fixed, paraffin-embedded serial sections 
of the same tumors analyzed by oligonucleotide microarray using standard procedures. After 
antigen retrieval by boiling for 10 min in 10 mM citrate buffer (pH 6.0) for Ki-67 and in 1.0 
mM EDTA buffer (pH 9.0) for Mum1/IRF4 tissue sections were incubated overnight with 
antibodies against respectively Ki-67 (clone MIB-1, 1:400, Dako, Glostrup, Denmark) and 
against Mum1/IRF4 (1:100; antibody was a kind gift of Professor G. Cattoretti, Institute for 
Cancer Genetics, Columbia University, New York, USA). Sections were then incubated with 
biotin-labeled rabbit-anti-mouse antibodies (1:200). Immunoreactivity was detected using a 
streptavidin-biotin-peroxidase complex (sABC-HRP, Dakocytomation K0377; 1:100; 
DAKO). Subsequently a 10 min incubation with DAB solution (Sigma) was performed. All 
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secondary and tertiairy antibodies were incubated for 30 min in 1% PBS/BSA at room 
temperature.
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RESULTS
 PCFCCL and PCLBCL-leg show distinct profiles of B-cell expressed genes
The microarray analysis of all tumor samples showed an average expression of 55% (range: 
52,1-58,8%) of all the 12625 genes represented on the oligonucleotide array. In the group of 
respectively PCFCCL and PCLBCL-leg an average number of 7098 and 7086 transcripts 
were present.
Unsupervised hierarchical clustering on the basis of all expressed genes separated 8 PCFCCL 
and 10 PCLBCL-leg in different groups, whereas three PCLBCL-leg (cases 12, 19 and 20) 
were clustered in the PCFCCL group (data not shown). However, unsupervised hierarchical 
clustering based on 7450 B-cell signature genes (see Materials and Methods) classified the 21 
PCLBCL into two distinct subgroups consisting of 8 PCFCCL and 13 PCLBCL-leg as shown 
by the dendrogram in Figure 1.
Differentially expressed genes in PCLBCL
Expression profiles of the entire set of genes of the 8 PCFCCL samples and the 13 PCLBCL-
leg samples were compared using the significance analysis of microarrays (SAM) technique 
to identify most differentiating genes between both groups. In this analysis all 12625 genes 
were included in order not to miss genes aberrantly expressed by tumor cells or genes that are 
expressed in late stages of B-cell differentiation (e.g. plasma cells), which are not covered by 
the generated B-cell signature. Seventy-one statistically significant differentially expressed 
genes at p<0.01 were identified as most discriminating genes between PCFCCL and 
PCLBCL-leg with fold changes of at least 3.0. Of these 71 most discriminating genes between 
PCFCCL and PCLBCL-leg, 48 genes were highly expressed in the group of PCLBCL-leg and 
23 genes were up-regulated in the group of PCFCCL as visualized in Figure 2.
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Clustering by biologic function showed that several of the 48 genes highly expressed in the 
group of PCLBCL were associated with cellular proliferation. These included cell cycle genes 
like Cyclin E, CDC6 and proliferating cell nuclear antigen (PCNA), genes involved in DNA 
synthesis and repair such as CTP-synthetase, DNA-polymerase and replication factors 3 and 5
and genes encoding transcription factors regulating cellular proliferation including Dp1, c-
Myc and Mybl2. Other genes highly up-regulated in the PCLBCL-leg group were IgM heavy 
chain and related genes involved in Ig mediated B-cell signaling, such as lyn and blk, the B-
cell transcription factors Mum1/IRF4 and Oct-2 as well as the genes encoding the Pim kinases 
(Pim-1 and Pim-2). As illustrated in Figure 2, the degree of up-regulation of most individual 
genes varied between individual samples of PCLBCL-leg. The most consistently 
overexpressed genes in almost all cases of the PCLBCL-leg group were IgM heavy chain 
(13/13 cases), Pim-1 (12/13 cases) and Mum1/IRF4 (12/13 cases). 
Of the 23 genes highly expressed in the group of PCFCCL no evident clusters of genes with 
similar biological function or involved in common pathways could be identified. However, 
the most prominent distinction between PCFCCL and PCLBCL-leg came from SPINK2 
which was highly expressed in all 8 PCFCCL samples with a fold change of 17.0. In addition, 
several genes associated with the reactive anti-tumor immune response were substantially up-
regulated in the group of PCFCCL, including granzyme M selectively expressed by NK-cells 
and the T-cell expressed genes selectin P and Lck which may reflect the higher number of 
admixed inflammatory cells in our group of PCFCCL. 
Gene expression of PCLBCL confirmed by quantitative real-time PCR
To validate the results of microarray analysis, quantitative real-time PCR (qPCR) was applied 
on a panel of 7 genes including c-Myc, Pim-1, Pim-2, Mum1/IRF4, Oct-2, Cyclin E and two 
splicevariants of Bcl-2 (Bcl-2 alpha and beta).  The fold changes in expression between 
PCFCCL and PCLBCL-leg resulting from qPCR analysis were calculated and compared with 
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the fold changes obtained by microarray analysis. Except for Cyclin E, qPCR results were all 
in agreement with oligonucleotide array results as shown in Figure 3. No statistically 
significant differences in Bcl-2 mRNA expression were found by qPCR between the PCFCCL 
and PCLBCL-leg groups, although the signals for the Bcl-2 beta splicevariant were slightly 
higher in the group of PCLBCL-leg. These qPCR measurements are in line with 
oligonucleotide array results as shown in Figure 3.
Immunohistochemistry
Because the Mum1/IRF4 transcript was consistently up-regulated in the group of PCLBCL-
leg, Mum1/IRF4 protein expression was investigated by immunohistochemistry in 11 
PCLBCL-leg and 5 PCFCCL. Tumor cells of 8 out of 11 PCLBCL-leg showed strong 
expression of Mum1/IRF4 (>80% positive staining cells) as shown in Figure 5A. In the other 
3 cases 30% (nos. 10 and 19) to 50% (no. 12) of the tumor cells were Mum1/IRF4 positive. In 
contrast, the tumor cells of all 5 PCFCCL were Mum1/IRF4 negative (10 % or less positive 
staining cells) as shown in Figure 5B. There was a good correlation between MUM1/IRF4 
protein and mRNA expression by microarray array with mean absolute expression value of 
MUM1/IRF4 of 322 (range: 172-437) for the 8 PCFCCL and 1570 (range: 397-2637) for the 
13 PCLBCL-leg. Although Mum1/IRF4 protein expression has been reported to have
prognostic significance in B-CLL, a relationship between Mum1/IRF4 expression and clinical 
outcome was not present in PCLBCL-leg.
25,26
To investigate proliferation rates of PCLBCL paraffin sections of the same tumors were also 
stained with an antibody against the proliferation marker Ki-67. Whereas Ki-67 was 
expressed by more than 75% of the tumor cells in all PCLBCL-leg, Ki-67 staining in 
PCFCCL was much more variable with percentages varying between 10% and 80% (median, 
35%).
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Activated B-cell profile versus germinal center B-cell profile
Several of the highly expressed genes in the PCLBCL-leg group including genes encoding for 
IgM heavy chain, Mum1/IRF4 and both Pim-kinases (Pim-1 and Pim-2) were recognized as 
members of the activated B-cell (ABC) profile identified by microarray analysis in a subset of 
nodal diffuse large B-cell lymphomas (DLBCL) characterized by an aggressive clinical 
behaviour.
27 Likewise a number of genes with high expression in PCFCCL including 
SPINK2, Lck and SLAM were included in the germinal center B-cell (GCB) profile 
corresponding to a subset of DLBCL with a more favorable clinical outcome. To test the 
hypothesis that PCLBCL-leg are related to ABC-like DLBCL and PCFCCL to GCB-like 
DLBCL, we used a recently described list consisting of 43 genes which discriminate both 
subgroups of DLBCL with highest significance.
28 These 43 genes were identified previously 
using the Affymetrix HU6500 microarray after the assignation of 274 DLBCL to ABC-type 
or GCB-type using a predictor model based on 14 genes represented on the Affymetrix 
HU6500 microarray out of 27 predictor genes of the lymphochip. All above mentioned genes, 
except Lck, were selected in this list as well. 
Hierarchical clustering based on the selected subset of these 43 genes clustered 7 out of 8 
PCFCCL and all 13 PCLBCL-leg together suggesting a similarity in gene expression profiles 
between PCLBCL-leg and ABC-like DLBCL and between PCFCCL and GCB-like DLBCL, 
respectively (Figure 4).
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DISCUSSION
In the EORTC classification of cutaneous lymphomas two types of PCLBCL are recognized: 
PCFCCL and PCLBCL-leg. The clinical, histological, immunophenotypical and genetic 
differences between both groups are summarized in Table 3. Although recent studies have 
provided further support for the clinical significance of this classification, there is still 
ongoing debate regarding the subdivision of PCLBCL into two main categories primarily 
based on site of presentation.
18-20 Understanding of the genetic mechanisms involved in the 
development and progression of these lymphomas might provide a solution for this 
controversy.
In the present study gene expression profiles of 8 PCFCCL with a diffuse large cell histology 
and 13 PCLBCL-leg were generated using Affymetrix® oligonucleotide arrays. Only cases in 
which large neoplastic B-cells constituted 80% or more of the total number of infiltrating cells 
were included in this study. Hierarchical clustering based on 7450 genes expressed in a 
created B-cell signature (see Materials and Methods), used to minimize the effect of non-
malignant cells present in the skin biopsies, classified the 21 PCLBCL into two distinct 
subgroups consisting of 8 PCFCCL and 13 PCLBCL-leg. Analysis of the expression of 43 
genes recently described to discriminate the ABC and GCB types of DLBCL with highest 
significance suggested a similarity between PCLBCL-leg and ABC-like DLBCL and 
PCFCCL and GCB-like DLBCL, respectively.
28 These observations do not only provide 
significant support for the subdivision used in the EORTC classification, but also suggests 
that different pathogenetic mechanisms are involved in the development of these two types of 
PCLBCL. Further analysis identified 71 statistically significant differentially expressed genes 
as most discriminating genes between PCFCCL and PCLBCL-leg with fold changes of at 
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least 3.0. Forty-eight genes were highly expressed in PCLBCL-leg and 23 genes showed high 
expression in PCFCCL. The high expression of 5 of 6 selected genes in PCLBCL-leg was 
confirmed by qPCR.
The increased cellular proliferative activity in PCLBCL-leg, as shown by the high expression 
of various genes associated with proliferation as well as the high percentages Ki-67 positive 
staining tumor cells (>75% in 12/13 cases), may probably be a result of the deregulated 
expression of several oncogenes with cell cycle regulatory functions, such as c-Myc, Pim-1, 
and Bcl-6.
29 In the group of PCLBCL-leg high expression of c-Myc was found, although the 
levels of gene expression values varied among individual samples. Interestingly, a correlation 
could be found between the highest c-Myc expression value on microarray and qPCR (case 
no. 12) and the presence of a chromosomal translocation involving the IgH gene and c-Myc 
gene (t(8;14)(q24;q32)) detected by FISH analysis performed in a separate study.
30 In a small 
CGH-array study Mao et al. showed gains of c-Myc (8q24) in 2 of 4 PCLBCL, but did not 
mention the localization of skin lesions in these cases.
17 The oncogene c-Myc is a 
transcription factor and has been proposed to be involved in multiple cellular functions such 
as cell cycle regulation, apoptosis, cell growth, metabolism and differentiation which might 
be cell type- and context-dependent.
29 Overexpression of the c-Myc gene by chromosomal 
translocation to the Ig loci is an important event in malignant transformation in virtually all 
Burkitt lymphomas, in 6% of DLBCL and recently found in 5 of 14 cases of PCLBCL-
leg.
1,30,31 Interestingly, we also observed high expression of the Pim-1 and Pim-2 oncogenes 
in PCLBCL-leg. Pim-kinases are known to cooperate with c-Myc and N-Myc to generate T-
and B-cell lymphomas, although the precise mechanism of this synergism in 
lymphomagenesis remains obscure.
32-35 Noteworthy, a second transcriptional key regulator of 
cellular proliferation, Bcl-6, is expressed by the tumor cells of almost all PCLBCL and its 
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deregulation may contribute to active cellular proliferation as well.
10,14 Recently, somatic 
hypermutations of the Bcl-6 gene have been detected in a small series of PCLBCL-leg, which 
may affect the Bcl-6 negative autoregulation circuit resulting in Bcl-6 deregulation as 
described in nodal diffuse large B-cell lymphoma.
12,36,37
Another prominent distinction between gene expression profiles of PCLBCL-leg and 
PCFCCL was the marked high expression of B-cell transcription factors Mum1/IRF4 and 
Oct-2 in PCLBCL-leg, both expressed in late plasma cell-directed B-cell differentiation 
stages.
38,39 Mum1/IRF4 is strongly expressed in lymphoplasmocytoid lymphoma, multiple 
myeloma and 75% of diffuse large B-cell lymphomas.
38  High Mum1/IRF4 expression in 
PCLBCL-leg was confirmed by qPCR and immunohistochemistry and is consistent with the 
results of a recent study.
12 Mum1/IRF4 is fused to the immunoglobulin locus in some cases of 
multiple myeloma and can function as an oncogene in vitro.
40 Mum1/IRF4 is transiently 
induced during normal lymphocyte activation and is critical for the proliferation of B 
lymphocytes in response to signals from the antigen receptor.
41,42 Thus, the constitutive 
expression of Mum1/IRF4 may also contribute to the unchecked proliferation of the 
malignant cells in PCLBCL-leg. In addition, in vitro experiments demonstrated that 
expression of Mum1/IRF4 enhances the susceptibility of lymphocytes to undergo Fas-induced 
apoptosis.
43 It has not yet been elucidated whether the Mum1/IRF4-mediated pro-apoptotic 
effects are selectively bypassed in Mum1/IRF4 expressing tumors, but it has been reported 
that Mum1/IRF4 function can be modulated by the presence of Bcl-6.
44 Given the 
coexpression of Bcl-6 and Mum1/IRF4 in PCLBCL-leg, it is possible that Bcl-6 may interfere 
with the pro-apoptotic effects of Mum1/IRF4.
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In the group of PCFCCL very high expression levels of the SPINK2 transcript were observed 
in all samples, except one, whereas expression of SPINK2 was very low or absent in all 
samples of PCLBCL-leg. Interestingly, SPINK2 was identified as the most differentially 
expressed gene between both groups with a remarkable high fold change of 17.0. 
Furthermore, SPINK2 was recognized as one of the genes of the germinal center genes of the 
43 genes which discriminate between the GCB and ABC types of DLBCL with highest 
significance.
28 The SPINK2 gene encodes a Kazal type serine threonine kinase with ill-
defined function in physiological and pathological cellular processes.
45 Further studies will be 
needed to elucidate the potential role of SPINK2 in the development of PCFCCL. In addition, 
several genes associated with the host immune response (granzyme M, selectin P, Lck) were 
substantially upregulated in the group of PCFCCL, which is consistent with the higher 
numbers of host immune cells in these tumors. This is also in line with previous observations 
in diffuse large B-cell lymphomas that genes associated with the host immune response and 
extracellular matrix components (both were considered part of the “lymph node signature”)
are more highly expressed in GCB tumors
46
Consistent with previous studies 
9, 10 we observed strong Bcl-2 protein expression in 11 of 13 
PCLBCL-leg, but not in the PCFCCL included for this study. Bcl-2 encoding mRNA 
expression values, however, did not statistically significantly differ between the two groups; 
Bcl-2 mRNA was detected in all patients both by using the microarray analysis (not 
discriminating between both splice variants) as well as qPCR analysis (for each individual 
splice variant). The presence of Bcl-2 mRNA despite the absence of Bcl-2 protein in the 
group of PCFCCL was unexpected, but has previously been described as a characteristic 
feature of germinal center B cells.
49,50 It was suggested that germinal center cells may be 
involved in some arrest of Bcl-2 protein expression at the posttranscriptional level.
47,48 Such
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a, hitherto unknown, mechanism might be conserved in PCFCCL and reflect a typical feature 
of its proposed germinal center B-cell origin. The mechanisms underlying the high bcl-2 
protein expression in PCLBCL-leg are at present unknown. Posttranslational modification 
such as ubiquitination of kinase sites or decreased degradation, for instance by inhibition of 
FRAP/RAFT/mTOR, leading to increased cellular concentration of bcl-2 protein unrelated to 
the amount of Bcl-2 mRNA might be a possible explanation.
49,50
In conclusion, the results of the present study provide molecular support for the view that 
PCFCCL and PCLBCL-leg are distinct subtypes of PCLBCL, as recognized in the EORTC 
classification. They also suggest different mechanisms of malignant transformation in these 
two types of PCLBCL. The observation that PCFCCL and PCLBCL-leg have gene expression 
profiles similar to that of GCB and ABC type of diffuse large B-cell lymphoma is clinically 
important. It is not only consistent with the much better prognosis of the group of PCFCCL, 
but also suggest that different therapeutic approaches are warranted in these two types of 
PCLBCL. 
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LEGENDS TO THE FIGURES
Figure 1. Hierarchical clustering based on B-cell signature in primary cutaneous large 
B-cell lymphoma.
Hierarchical clustering based on the expression of a B-cell signature consisting of 7450 genes 
with a "present"-call in normal B-cell subsets (centroblasts, centrocytes, memory B-cells and 
naïve B-cells) and generated by the same Affymetrix U95Av2 Gene Chip
22 identifies two 
distinct gene expression profiles in primary cutaneous follicle center cell lymphoma 
(PCFCCL) and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg).
Figure 2. Differentiating genes in primary cutaneous large B-cell lymphoma.
Seventy-one statistically significant differentially expressed genes identified as most discriminating 
genes between primary cutaneous follicle center cell lymphoma (PCFCCL) and primary cutaneous 
large B-cell lymphoma of the leg (PCLBCL-leg) with fold changes of at least 3.0 were classified by 
biological function. Forty-eight genes were highly expressed in the group of PCLBCL-leg and 23 
genes were up-regulated in the group of PCFCCL. Genes indicated by an asterisk (*) were not present 
in the B-cell signature.
22
Figure 3.  Results of quantitative real-time PCR analysis (qPCR). 
Histogram showing expression of 6 selected differentially expressed genes and Bcl-2 alpha and beta 
splicevariants as measured by oligonucleotide microarray analysis (￿) and in 4 primary cutaneous 
follicle center cell lymphoma and 4 primary cutaneous large B-cell lymphoma of the leg by qPCR 
(￿).Fold changes of oligonucleotide microarray and qPCR experiments derived data denote average 
expression level in patients relative to each other. A fold change of 1 indicates equal expression in both 
groups. The error bars represent standard deviations of the mean expression values as measured by 
qPCR. 
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Figure 4. Expression of activated B-cell profile and germinal center profile genes in primary 
cutaneous large B-cell lymphoma.
Hierarchical clustering analysis of primary cutaneous follicle center cell lymphoma 
(PCFCCL) and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg) was 
performed based on the expression of 43 genes present in a recently described list consisting 
of 43 genes which discriminate between activated B-cell (ABC) and germinal center B-cell 
(GCB) types of diffuse large B-cell lymphoma with highest significance.
27 These 43 genes 
were identified previously using the Affymetrix HU6500 microarray after the assignation of 
274 DLBCL to ABC type or GCB type using a predictor model based on 14 genes 
represented on the Affymetrix HU6500 microarray out of 27 predictor genes of the 
lymphochip. Hierarchical clustering based on these 43 selected genes clustered respectively 
7/8 PCFCCL and 13/13 PCLBCL-leg in two distinct groups.
Figure 5. Expression of Mum1/IRF4 in primary cutaneous large B-cell lymphoma.
Neoplastic B-cells of primary cutaneous large B-cell lymphoma of the leg show a positive 
staining for Mum1/IRF4 (A), whereas neoplastic cells of primary cutaneous follicle center 
cell lymphoma are Mum1/IRF4 negative (B). (original magnification x200).
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TABLES
Table 1. Clinical characteristics of patients with primary cutaneous large B-cell lymphoma.
case no. clinical 
presentation
sex / 
age at 
diagnosis
initial
therapy
result of
initial therapy
relapse follow-up status,
period in months
PCFCCL
1 multiple tumors on the scalp M / 76 RT  CR none D-, 36
2 localized tumours on the chest M / 38 RT CR none A-, 192
3 localized plaques and tumors on 
the back
M / 62 RT CR skin + EC D-, 41
4 grouped plaques and tumors on 
the scalp
M / 61 RT CR skin A-, 109
5 solitary tumor on the scalp F / 69 RT CR none A-, 127
6 solitairy tumor on the scalp   M / 37 RT CR skin A-, 68
7 grouped plaques and tumors on 
the chest 
F / 50 RT CR none A-, 24
8 solitary tumor on the scalp M / 55 RT CR none A-, 8
PCLBCL-leg
9 tumors on right cheek and right 
upper leg
M / 69 CHOP CR skin + EC D+, 35
10 3 tumors on left lower leg M / 47 CHOP CR none A-, 32
11 multiple tumors on right lower leg F / 84 CHOP CR skin A-, 30
12 2 tumors on left lower leg F / 74 CHOP CR none A-, 30
13 solitary tumor lower leg F / 62 RT CR none D-, 36
14 multiple tumors on left lower leg M / 89 CHOP CR skin + EC D+, 12
15 multiple tumors on left lower leg F / 90      PUVA-
   phototherapy
PR skin + EC D+, 29
16 solitary tumor on left lower leg F / 88 RT CR skin + EC D+, 26
17 tumors and plaque on right lower 
leg
F / 77 RT CR skin A-, 45
18 solitary tumor on left lower leg  F / 83 RT CR EC D+, 24
19 multiple tumors on both legs F / 76 CHOP CR skin         D-, 11
20 multiple tumors on both lower 
legs
F / 75 CHOP CR  none  A-, 12
21 solitary tumor on right lower leg F / 75 RT CR skin + EC D+, 73
Abbreviations: 
PCFCCL = primary follicle center cell lymphoma, PCLBCL-leg = primary cutaneous large B-cell lymphoma of 
the leg, CHOP = multiagent anthracycline-based chemotherapy, RT = radiotherapy, CR = complete remission, 
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PR = partial remission, EC = extracutaneous relapse, A- = alive with no evidence of disease, A+ = alive with 
disease, D+ = died of lymphoma, D- = died of other cause
Table 2. Primers sequences and accession numbers of selected transcripts quantified by real-
  time PCR. 
gene Accession 5' primer      3' primer
Pim-1  NM_002648 CCAGCAAATAGCAGCCTTTC GTCACTGGTACTCGGGAAGC
Pim-2  NM_006875 TTGGGAAGGAATGGAAGATG TTATTTCCCCTAGCCCATCC
Cyclin E NM_001238 AGCGGTAAGAAGCAGAGCAG CGCTGCAACAGACAGAAGAG
Oct-2  NM_002698 AGAGGAGATCCTGCTGATCG GGTTGATGCGTTTCTCCTTC
c-Myc NM_002467 AGATCCCGGAGTTGGAAAAC AGCTTTTGCTCCTCTGCTTG
Mum-1  NM_002460 TTACCACCAAGGGCAGGTAG ACCCAAGACTCCCACAGTTG
Bcl-2 alpha NM_000633 GCCCTGTGGATGACTGAGTA GGCCGTACAGTTCCACAAAG
Bcl-2 beta NM_000657 GCCCTGTGGATGACTGAGTA ATCACCAGATGCACCTACCC
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Table 3. Clinical, histological, immunophenotypical and genetic differences between PCFCCL 
  with a diffuse large cell histology and PCLBCL-leg.
PCFCCL
(diffuse large cell)
PCLBCL-leg References
Clinical features
- median age at 
  diagnosis (range)
62 (14-88) 75 (27-92) 7, 8, 9, 11
- male:female ratio 1 : 1 3 : 1 7, 8, 11 
- site trunk; head (scalp) leg(s) 1
- treatment of first choice  radiotherapy systemic chemotherapy 1, 7
- dissemination 11% 50% 7, 8
- 5-year survival >95% 52% 7, 8
Histopathology
- cytomorphology large cleaved (85%) round (90%) 3, 4, 5, 7, 8
- blastic transformation Often [1] no (de novo) 3, 4, 5, 7, 8
- Bcl-2 expression - / + [2] + 9, 10, 11
- Bcl-6 expression + + / - 10, 11, 12
- CD10 expression - - 10, 12
- Mum1/IRF4 expressie - + present study, 12
Genetics
- t(14;18) absent absent 9, 15, 16, 18
- CGH analysis 18
- loss 6q 0 / 9 4 / 13
- gain 18q 0 / 9 8 / 13
- FISH analysis 29
- IgH breakpoint 0 / 6 7 / 14
- c-Myc breakpoint 0 / 6 6 / 14 
- Bcl-6 breakpoint 0 / 6 5 / 14
gene expression profile germinal center B-cell 
type (GCB)
activated B-cell type 
(ABC)
present study
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[1]: may sometimes be preceded by PCFCCL with a predominance of small centrocytes and/or 
follicular growth pattern
[2]: may be weakly positive in a minority of tumor cells
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Figure 2
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3.2 selectin P* (CD62) (SELP) 
3.0 cell adhesion molecule with homology to L1CAM (CHL1)
3.3 reversion-inducing-cysteine-rich protein with Kazal motifs (RECK)
4.0 minor histocompatibility antigen HB-1 (HB-1)
3.8 adenosine deaminase, RNA-specific, B1 (ADARB1)
7.1 signaling lymphocytic activation molecule (SLAM) 
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Figure 4
TPM2
KIAA0171
KIAA0084
IGHM
PRKCB1
FUT8
GOT2
IRF4
P2RX5
BAT
SLA
SPI140
PTPN1
PSIP2
DC
KRT8
RTVP1
TCF4
HMG14
MYBL1
GPR18
CST
FAM3
SPINK2
HLA-
LMO2
ITPKB
SLA
HLA-
VCL
PLEK
LRM
RPL21
SCA1
CXCR4
MARCK
SPIB
PIM2
BCL2
CCND
PIM1
CSNKIE
ACP1
PCFCCL
PCLBCL-leg
5      20    19    12    16      9     17    18    14    10     11     21    15    13     3       1      7      6       4      2      8
2              0                -2
z-
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 37
Figure 5
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